Form 4: Oruka Therapeutics Director Acquires Stock Options

Oruka Therapeutics Director Christopher Martin acquired stock options for 9,136 shares of common stock.

Summary

• Christopher Martin, a Director at Oruka Therapeutics, Inc., acquired stock options on June 2, 2026.
• The options grant the right to buy 9,136 shares of common stock at an exercise price of $55.23 per share.
• These options have an expiration date of June 1, 2036.
• The options vest monthly, with 1/12 of the underlying shares becoming available each month starting from June 2, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it's a standard director option grant and vesting schedule, not indicative of immediate positive or negative news.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price suggests a potential for future stock appreciation.

Future Outlook

The acquisition of stock options by a director, with a vesting schedule, indicates a long-term perspective on the company's potential growth and stock value.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a form of executive compensation and to align management interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially leading to increased focus on long-term value creation.

Next Steps

• Monthly vesting of stock options commencing June 2, 2026.
• Potential exercise of stock options by Christopher Martin up to June 1, 2036, subject to vesting.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act